# Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

> **NCT00789854** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 688 (actual)

## Conditions studied

- Major Depressive Disorder
- Treatment Resistant Depression

## Interventions

- **DRUG:** Quetiapine XR
- **DRUG:** Lithium carbonate
- **DRUG:** SSRI/Venlafaxine

## Key facts

- **NCT ID:** NCT00789854
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 688 (ACTUAL)
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789854, "Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00789854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*